Lung cancer is one of the most lethal diseases worldwide, and the survival rate is less than
15% even after the treatment. Unfortunately, chemotherapeutic treatments for lung cancer …

According to global statistics, cancer is the second leading cause of death worldwide.
Because of the heterogeneity of cancer, single‐drug therapy has many limitations due to low …

Lung cancer is the second most diagnosed cancer in both men and women worldwide.
Considering the high mortality rate of lung cancer and inadequacy of conventional treatment …

Despite major progress in both therapeutic and diagnostic techniques, lung cancer is still
considered the leading cause of cancer mortality in the world due to the ineffectiveness of …

Research on siRNA is increasing due to its wide applicability as a therapeutic agent in
irreversible medical conditions. siRNA inhibits expression of the specific gene after its …

Non-hepatic delivery of small interfering RNA (siRNA) remains a challenge for the
development of RNA interference (RNAi)-based therapeutics. Inhalation is a straightforward …

RNA interference (RNAi), which can inhibit the expression or transcription of specific genes,
is considered to be a revolutionary tool for mediating gene therapy. Small interfering RNA …

RNA interference (RNAi) is a naturally occurring regulatory process that controls
posttranscriptional gene expression. Small interfering RNA (siRNA), a common form of RNAi …

Various delivery strategies, involving siRNA as a therapeutic tool for gene silencing, have
been highlighted through several investigations all over the world. One such medical target …

Resistance to chemotherapy, enhanced proliferation, invasion, angiogenesis, and
metastasis (RPIAM) represent major obstacles that limit the efficacy of cancer treatment …